Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Takaichi Highlights Drug Discovery as Crucial Growth Field in LDP Race
Former economic security minister Sanae Takaichi on September 19 announced her bid for the ruling Liberal Democratic Party (LDP) presidency, pledging to strengthen economic security by prioritizing drug discovery and advanced medicine as “crucial growth areas” alongside artificial intelligence and…
To read the full story
Related Article
- Takaichi Faces Tough Balancing Act on Healthcare, Nursing Reform
October 22, 2025
- LDP’s Takaichi Elected as Japan’s First Female Prime Minister
October 22, 2025
- LDP, Nippon Ishin to Form Coalition; OTC-Like Drug Copay Review Set for FY2025
October 21, 2025
- Komeito’s Exit from Ruling Coalition Casts Uncertainty over Japan’s Drug Policy
October 15, 2025
- Pharma Industry Generally Welcomes New LDP Leader Takaichi
October 7, 2025
- Takaichi Vows Hospital Support via Extra Budget; MHLW Sees Boost for Funding Requests
October 7, 2025
- LDP Leadership Race Underway, Healthcare-Savvy Lawmakers Among Endorsers
September 24, 2025
- Hayashi Stresses Drug Discovery as Key Growth Field in LDP Race
September 19, 2025
- Motegi Calls for Lowering Generic Prices by Consolidation: LDP Race
September 11, 2025
REGULATORY
- Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned
January 23, 2026
- DPP Vows to Scrap Off-Year Drug Price Revisions in Election Platform
January 23, 2026
- Japan Starts Review on Scope of Drugs Eligible for Immunization Use, with Beyfortus in Focus
January 23, 2026
- Takeda’s Miyabashira Urges National Strategy Act to Revive Japan as Innovation Powerhouse
January 22, 2026
- LDP Pledges to Position Pharma as Core Industry in Campaign Platform
January 22, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…